Global Cystic Fibrosis Market worth $7.7bn in 2021

This new report, now available on ASDReports, the Global Cystic Fibrosis Therapeutics Market 2016-2026: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies indicates that the Global Cystic Fibrosis market will see $7.7bn in spending in 2021.

The lead analyst of the report said: “The cystic fibrosis market is poised for a rapid growth year-on-year. The major driver of cystic fibrosis market is the new product launches in CFTR modulator class. The market share of CFTR modulator therapies is nearly half at 51% of the total therapeutic share in 2016. The key player expects the global cystic fibrosis market to grow at a very strong pace of CAGR 16.7% from 2016 until 2021. This growth is mainly driven by the expected rapid uptake of Orkambi (Vertex Pharmaceuticals).”

The 191 page report contains 113 tables, charts and graphs that add visual analysis in order to explain developing trends within the Global Cystic Fibrosis market. The key player provides revenue forecasts for the period 2016-2026 as well as qualitative analyses for the leading segments of this market, which include:

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
Protein Transcription Modulators
Pancreatic Enzyme Products (PEP)
Other therapies

This report offers individual drug forecast and analysis of the 9 leading cystic fibrosis drugs. In addition, this report provides patent analysis of marketed and pipeline products for cystic fibrosis.

This 191 page report provides revenue, growth forecasts and discussion of relevant trends and developments in the leading national cystic fibrosis market. The dynamic of pricing, patient share and market share of the leading cystic fibrosis drugs in the US and Europe are also discussed.